Skip to content

Comparison of endoscopic healing and durability between combination therapy with infliximab and azathioprine versus infliximab monotherapy in pediatric Crohn's disease

Document Type
Publications · Journal Article
Registered DB
SCIEScopus
Journal Ranking
JCR Q1Scopus Q1
Journal
SCIENTIFIC REPORTS15(1) · #23025 · 2025
Citation
Web of Science 0Scopus 0
FWCI (Scopus)
0
JCR IF
JCR 2024 3.9
ISSN
2045-2322

Authors

  1. Kim, Yoon ZiFirst authorSungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Pediat, Seoul, South Korea
  2. Kim, Eun SilSungkyunkwan Univ, Sch Med, Kangbuk Samsung Hosp, Dept Pediat, Seoul, South Korea
  3. Kwon, YiyoungSungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Pediat, Seoul, South Korea
  4. Kim, Seon YoungKyung Hee Univ Hosp, Dept Pediat, Seoul, South Korea
  5. Kim, HansolPusan Natl Univ, Dept Pediat, Yangsan Hosp, Yangsan, South Korea
  6. Choe, Yon HoCorresponding authorSungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Pediat, Seoul, South Korea
  7. Kim, Mi JinCorresponding authorSungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Pediat, Seoul, South Korea

Abstract

This retrospective observational study evaluated the effectiveness of endoscopic healing (EH) and the durability of infliximab (IFX) in combination with azathioprine (AZA) versus IFX monotherapy in pediatric patients with Crohn's disease (CD). EH was assessed after 1 year of treatment, whereas IFX durability and associated risk factors were evaluated over an extended follow-up period. Data from 108 pediatric patients were analyzed by comparing the EH rates, IFX trough levels (TLs), antibody-to-IFX (ATIs), and IFX durability between the AZA combination therapy (combination therapy group) and IFX monotherapy (monotherapy group) groups. Of the 108 patients who received IFX therapy, 85 (78.7%) received AZA combination therapy, and 23 (21.3%) received IFX monotherapy. The combination therapy group demonstrated superior EH rates (78.6 vs. 33.3%, p < 0.001), higher IFX TLs (4.6 g/mL vs. 3.9 mu g/mL, p = 0.016), lower ATI positivity (25.0% vs. 52.2%, p = 0.025), and prolonged IFX durability than the monotherapy group. Multivariable Cox proportional hazard regression analysis showed that ATI positivity (hazard ratio [HR] 5.33, 95% confidence interval [CI] 1.61-17.60, p = 0.006) and combination therapy with IFX and AZA (HR 0.13, 95% CI 0.03-0.51, p = 0.004) were associated with IFX durability.

Keywords

Inflammatory bowel diseaseEndoscopic healingInfliximabDurabilityPediatricINFLAMMATORY-BOWEL-DISEASECHILDRENIMMUNOSUPPRESSIONANTIBODIESREMISSIONMODERATE

Identifiers

Scopus EID
2-s2.0-105010059767
WoS UID
001522987300018